OneSource Specialty Pharma: Karnataka nod for Unit II 2026

Stock snapshot and why the update matters

OneSource Specialty Pharma’s latest regulatory update is tied to its core manufacturing footprint in Karnataka, where Unit II is positioned as the company’s flagship facility for global partners. The company said it received in-principle approval from the Government of Karnataka for its Unit II expansion project under the Karnataka Industrial Policy (KIP) 2025-30. The approval covers incentives and concessions, which can influence project economics and execution planning for capacity additions.

On the market side, the stock was at ₹1,834.80, up 0.82% on the day (₹14.90). The company’s market capitalisation was shown at ₹21,030.70 crore, with a reported PE ratio of -282.66. Recent price performance data showed gains of 18.75% over one month, 5.94% over six months, and 14.73% over one year.

Karnataka’s in-principle approval: what the company disclosed

The company said it received a Government Order bearing No. CI 120 SPI 2026 dated May 12, 2026, and that it received the order on May 15, 2026. The in-principle approval relates specifically to Unit II expansion under KIP 2025-30, and it includes incentives and concessions. The company linked the decision to the 67th State High Level Clearance Committee meeting held on April 13, 2026.

In its description of Unit II, OneSource called it its flagship facility located at Obadenahalli, KIADB Industrial Area, Bengaluru Rural District. The company said the expansion is intended to enhance manufacturing capacities aimed at servicing global partners. No capex number, timeline, or specific capacity figure was provided in the supplied text.

Why Unit II sits at the centre of OneSource’s manufacturing narrative

Multiple disclosures in the provided material position Unit II as a key regulated site. OneSource previously announced renewal of EU-GMP certification for Unit II on April 17, 2026, following an inspection by European regulatory authorities. The company described the site as an integrated biologics facility focused on drug-device combinations and sterile injectable products.

Separately, OneSource had also disclosed that Unit 2 in Bengaluru received GMP certification from ANVISA, Brazil’s health regulatory agency, following a successful inspection held in November 2024. The company said that approval enables supply to Brazil once customers receive product approvals, and it highlighted GLP-1 related opportunities in that context.

Semaglutide-related partner updates across markets

OneSource has referenced semaglutide-linked collaborations and approvals in multiple markets. It said it supports partner Orbicular in securing Health Canada approval for generic semaglutide injection, describing it as the second generic approval in Canada’s semaglutide market. The company stated it will provide commercial supply from its US FDA-approved Bengaluru facility.

In another update, OneSource announced Orbicular received tentative US FDA approval for generic Ozempic (Semaglutide Injection), with OneSource acting as the CDMO manufacturing partner. The company also disclosed SFDA approval in Saudi Arabia for its generic Ozempic (semaglutide), alongside an exclusive partnership with Hikma Pharmaceuticals for MENA commercialisation, with OneSource handling manufacturing from Bengaluru.

The company has also stated it plans to sell semaglutide once regulatory approvals are received, while also highlighting that semaglutide is not its only growth driver.

Corporate actions: ESOP allotments and share capital changes

OneSource disclosed multiple ESOP-related allotments in 2026. It allotted 3,150 equity shares of ₹1 each on May 13, 2026 under ONESOURCE ESOP 2021, issued at an exercise price of ₹278 per share (premium of ₹277 per share). Following this allotment, paid-up share capital increased from ₹11,46,42,651 to ₹11,46,45,801, and total issued shares rose to 11,46,45,801.

Earlier, it allotted 21,450 equity shares on April 9, 2026 at ₹278 per share, increasing paid-up share capital from ₹11,46,21,201 to ₹11,46,42,651. It also allotted 36,065 equity shares on January 21, 2026 at ₹278 per share, taking total equity shares to 11,46,21,201.

Pledge disclosures tied to a ₹1,000 crore debenture security

The provided text includes disclosures around promoter share pledges and debenture-related security. Catalyst Trusteeship disclosed an additional pledge of 28,36,811 equity shares by Tenshi Pharmaceuticals Private Limited, taking total pledged shares to 92,36,811, stated as 8.06% of share capital. The pledge was described as security for ₹1,000,00,00,000 worth of debentures issued by group company Karuna Ventures Private Limited, with additional shares pledged in multiple tranches between January and March 2026.

OneSource also disclosed that Tenshi Pharmaceuticals pledged 64,00,000 equity shares (5.59% stake) to Catalyst Trusteeship as security for ₹1,000 crore debentures, with the encumbrance created on January 5, 2026 under agreements dated November 27, 2025. An earlier disclosure referenced a pledge of 20,00,000 shares in December 2025 for business and operational needs of the promoter entity.

Financial performance datapoints cited in the supplied material

The dataset includes quarterly and half-year performance figures for FY2025-26. OneSource reported Q2 FY2025-26 revenue up 15.7% QoQ to ₹378.763 crore and consolidated net profit of ₹10.485 crore, compared with a loss of ₹0.186 crore in Q1. For H1 FY2025-26, revenue was ₹706.033 crore with profit of ₹10.299 crore, described as a turnaround from the prior year’s loss.

In another results note, OneSource reported Q2FY26 revenue up 12% to ₹375.8 crore and an EBITDA margin of 28%, up by 506 basis points. It also reported signing 9 new MSAs and highlighted a raised FY28 revenue outlook to $100 million with an expected 40% EBITDA margin, while another disclosure said the company maintained an FY28 revenue target of $100 million.

Scheme and listing milestones referenced in company background

The supplied background also outlines the demerger-led formation of the unified CDMO platform, with an appointed date of April 1, 2024. It states the NCLT Mumbai Bench approved the scheme by order dated November 11, 2024, and that it became effective on November 27, 2024. The company’s equity shares commenced trading on NSE and BSE on January 24, 2025.

It also references a private placement of 6,277,909 fully paid-up equity shares at ₹1,276 each, raising ₹801 crore (also described as ~USD 95 million) at a pre-money valuation of USD 1.65 billion.

Key facts table

Market impact: what investors can and cannot infer from this update

The Karnataka in-principle approval is relevant because it links Unit II expansion to a state industrial policy framework that includes incentives and concessions. Based on the supplied information, the announcement does not quantify the incentives, project cost, or the incremental capacity being added, so the financial impact cannot be calculated from this disclosure alone.

Still, the broader set of updates show the company repeatedly emphasising regulated manufacturing readiness at its Bengaluru site, including EU-GMP renewal and ANVISA certification. Separately, semaglutide-related partner approvals and tentative approvals point to CDMO supply opportunities across multiple jurisdictions, with OneSource positioning Unit II and its Bengaluru facility as manufacturing backbones.

Conclusion

OneSource Specialty Pharma’s disclosure of Karnataka’s in-principle approval under KIP 2025-30 adds a policy-linked layer to its Unit II expansion plans at Obadenahalli. The update sits alongside a steady stream of regulatory site credentials and partner-led product approvals tied to complex injectables and drug-device combinations. The next concrete milestone to watch, based on the provided material, is further company communication on Unit II expansion specifics following the Government Order received on May 15, 2026.